Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study.

Autor:	Jameson A; Bradford District Care NHS Foundation Trust, Bradford, UK.; School of Pharmacy & Medical Sciences, University of Bradford, Bradford, UK.; Wolfson Centre for Applied Health Research, Bradford, UK., Faisal M; Wolfson Centre for Applied Health Research, Bradford, UK.; Faculty of Health Studies, University of Bradford, Bradford, UK.; NIHR Yorkshire and Humber Patient Safety Research Collaboration (YH PSRC), Bradford, UK., Fylan B; School of Pharmacy & Medical Sciences, University of Bradford, Bradford, UK.; Wolfson Centre for Applied Health Research, Bradford, UK.; NIHR Yorkshire and Humber Patient Safety Research Collaboration (YH PSRC), Bradford, UK., Bristow GC; School of Pharmacy & Medical Sciences, University of Bradford, Bradford, UK., Sohal J; Bradford District Care NHS Foundation Trust, Bradford, UK., Dalton C; Biomolecular Sciences Research Centre, Sheffield Hallam University, Sheffield, UK., Sagoo GS; Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK., Cardno AG; Leeds Institute of Health Sciences, Faculty of Medicine and Health, University of Leeds, Leeds, UK., McLean SL; School of Pharmacy & Medical Sciences, University of Bradford, Bradford, UK.; Wolfson Centre for Applied Health Research, Bradford, UK.
Jazyk:	angličtina
Zdroj:	Journal of psychopharmacology (Oxford, England) [J Psychopharmacol] 2024 Apr; Vol. 38 (4), pp. 382-394. Date of Electronic Publication: 2024 Mar 17.
DOI:	10.1177/02698811241238283
Abstrakt:	Background: Prescribing drugs for psychosis (antipsychotics) is challenging due to high rates of poor treatment outcomes, which are in part explained by an individual's genetics. Pharmacogenomic (PGx) testing can help clinicians tailor the choice or dose of psychosis drugs to an individual's genetics, particularly psychosis drugs with known variable response due to CYP2D6 gene variants ('CYP2D6-PGx antipsychotics'). Aims: This study aims to investigate differences between demographic groups prescribed 'CYP2D6-PGx antipsychotics' and estimate the proportion of patients eligible for PGx testing based on current pharmacogenomics guidance. Methods: A cross-sectional study took place extracting data from 243 patients' medical records to explore psychosis drug prescribing, including drug transitions. Demographic data such as age, sex, ethnicity, and clinical sub-team were collected and summarised. Descriptive statistics explored the proportion of 'CYP2D6-PGx antipsychotic' prescribing and the nature of transitions. We used logistic regression analysis to investigate associations between demographic variables and prescription of 'CYP2D6-PGx antipsychotic' versus 'non-CYP2D6-PGx antipsychotic'. Results: Two-thirds (164) of patients had been prescribed a 'CYP2D6-PGx antipsychotic' (aripiprazole, risperidone, haloperidol or zuclopenthixol). Over a fifth (23%) of patients would have met the suggested criteria for PGx testing, following two psychosis drug trials. There were no statistically significant differences between age, sex, or ethnicity in the likelihood of being prescribed a 'CYP2D6-PGx antipsychotic'. Conclusions: This study demonstrated high rates of prescribing 'CYP2D6-PGx-antipsychotics' in an EIP cohort, providing a rationale for further exploration of how PGx testing can be implemented in EIP services to personalise the prescribing of drugs for psychosis. Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu